# Cytognosis Foundation Master Data Strategy

> **Status**: Active
> **Date**: 2026-06-14
> **Author**: @mohammadi
> **Audience**: engineers, researchers, compliance, stakeholders
> **Tags**: `data-strategy`, `fair`, `hipaa`, `governance`

## Executive Summary

Cytognosis Foundation is developing AI-native healthcare technologies that detect and prevent disease before symptoms emerge. Our data strategy focuses on creating a comprehensive, ethical, and globally accessible framework for multimodal health data integration while maintaining the highest standards of privacy, security, and regulatory compliance.

## Vision & Mission

### Vision

A world where preventive healthcare is accessible to all through AI-driven early detection and intervention, supported by diverse, representative, and ethically managed health datasets.

### Mission

To develop and maintain a world-class data infrastructure that enables breakthrough AI research in preventive healthcare while ensuring privacy, equity, and global accessibility.

## Strategic Objectives

### 1. Multimodal Data Integration

**Objective**: Create unified datasets combining genomics, proteomics, imaging, clinical, and behavioral data.

**Key Initiatives**:

- Develop standardized data collection protocols across modalities
- Implement FHIR-compliant data models for interoperability
- Create AI-optimized data structures for machine learning
- Establish quality assurance frameworks for data validation

### 2. Privacy-Preserving AI Development

**Objective**: Advance AI research while maintaining strict privacy protections and regulatory compliance.

**Key Initiatives**:

- Implement federated learning architectures
- Develop differential privacy techniques for health data
- Create secure multi-party computation frameworks
- Establish privacy-preserving synthetic data generation

### 3. Global Health Equity

**Objective**: Ensure datasets represent diverse populations and address global health disparities.

**Key Initiatives**:

- Partner with healthcare systems in underserved regions
- Develop culturally sensitive data collection protocols
- Create bias detection and mitigation frameworks
- Establish equitable data sharing agreements

### 4. Open Science & Collaboration

**Objective**: Accelerate global health research through responsible data sharing and collaboration.

## The FAIRification Process & Principles

Cytognosis Foundation legally mandates that **all** public and controlled-access datasets undergo a rigorous **FAIRification Process** prior to distribution. Data is useless if it cannot be discovered or understood by machines and external researchers.

Every dataset must satisfy the 15 **FAIR Guiding Principles** (Wilkinson et al., 2016):

### 1. **F**indable

- **F1**: (Meta)data are assigned a globally unique and persistent identifier (PID).
- **F2**: Data are described with rich metadata.
- **F3**: Metadata clearly and explicitly include the identifier of the data they describe.
- **F4**: (Meta)data are registered or indexed in a searchable resource.

### 2. **A**ccessible

- **A1**: (Meta)data are retrievable by their identifier using a standardized communications protocol.
  - **A1.1**: The protocol is open, free, and universally implementable.
  - **A1.2**: The protocol allows for an authentication and authorization procedure, where necessary (critical for HIPAA/PHI data).
- **A2**: Metadata are accessible, even when the data are no longer available.

### 3. **I**nteroperable

- **I1**: (Meta)data use a formal, accessible, shared, and broadly applicable language for knowledge representation.
- **I2**: (Meta)data use vocabularies that follow FAIR principles (e.g., standard biomedical ontologies).
- **I3**: (Meta)data include qualified references to other (meta)data.

### 4. **R**eusable

- **R1**: (Meta)data are richly described with a plurality of accurate and relevant attributes.
  - **R1.1**: (Meta)data are released with a clear and accessible data usage license.
  - **R1.2**: (Meta)data are associated with detailed provenance.
  - **R1.3**: (Meta)data meet domain-relevant community standards.

## Public Dataset Portfolio (2025-2030)

### 1. Cytognosis Multimodal Prevention Dataset (CMPD)

**Description**: De-identified multimodal health data for early disease detection research
**Data Types**: Genomic variants, proteomic biomarkers, imaging, clinical labs, lifestyle factors.
**Access**: Open access with data use agreement

### 2. Global Health Disparities Dataset (GHDD)

**Description**: Comprehensive dataset addressing health disparities across populations
**Data Types**: Social determinants, access metrics, population outcomes.
**Access**: Open access with attribution requirement

### 3. AI-Ready Preventive Care Dataset (ARPCD)

**Description**: Longitudinal dataset optimized for AI/ML model development
**Access**: Controlled access with research proposal review

### 4. Federated Learning Benchmark Dataset (FLBD)

**Description**: Standardized datasets for federated learning research in healthcare
**Access**: Open access with technical requirements

### 5. Cytognosis Synthetic Health Dataset (CSHD)

**Description**: High-fidelity synthetic health data for unrestricted research use
**Access**: Completely open with no restrictions

## Privacy-Preserving Technologies

### De-identification Framework

- **Safe Harbor Method**: Remove 18 HIPAA identifiers
- **Expert Determination**: Statistical disclosure control
- **K-anonymity**: Minimum group size requirements (k≥5)
- **L-diversity**: Sensitive attribute diversity
- **T-closeness**: Distribution similarity constraints

### Advanced Privacy Techniques

- **Differential Privacy**: Formal privacy guarantees with ε-δ privacy
- **Homomorphic Encryption**: Computation on encrypted data
- **Secure Multi-party Computation**: Collaborative analysis without sharing
- **Federated Learning**: Model training without centralized data

## Data Governance Framework

### Governance Structure

```text
Data Governance Committee
├── Chief Data Officer (CDO)
├── Privacy Officer
├── Compliance Officer
├── Research Director
└── External Advisory Board
    ├── Medical Ethics Expert
    ├── Privacy & Security Specialist
    ├── Regulatory Affairs Professional
    └── Patient Advocacy Representative
```

### Access Control Models

1. **Open Access**: No registration, attribution required only.
2. **Controlled Access**: Research proposal required, DUA execution, institutional affiliation.
3. **Federated Access**: On-site analysis only, algorithms vetted prior to execution.

## Technical Architecture

### Data Infrastructure

```text
Data Lake (Encrypted)
├── Raw Data Ingestion
│   ├── Multi-omics Pipeline
│   └── Clinical Data Pipeline
├── Data Processing & Validation
│   ├── Quality Assurance
│   ├── Standardization
│   └── De-identification
├── Federated Learning Platform
│   └── Privacy Preservation Platform
└── Data Distribution Layer
```

### Security & Privacy Controls

- **Encryption**: AES-256 at rest, TLS 1.3 in transit
- **Access Control**: Role-based with multi-factor authentication
- **Audit Logging**: Comprehensive access and modification logs
- **Data Minimization**: Purpose-limited collection and processing

## Regulatory Compliance Ecosystem

### HIPAA Compliance (US)

- **Administrative Safeguards**: Policies, training, BAAs, incident response
- **Technical Safeguards**: Access controls, encryption, audit logs

### GDPR Compliance (EU)

- **Lawful Basis**: Consent, scientific research exemptions
- **Data Subject Rights**: Automated handling for erasure & access

### FDA Guidelines

- **Software as Medical Device (SaMD)**: Risk-based classification
- **Clinical Validation**: Analytical/clinical performance audits

## International Partnerships & Collaborations

- **Academic**: Harvard T.H. Chan, Oxford Big Data Institute, MIT CSAIL
- **Health Systems**: Partners HealthCare, NHS Digital, UK Biobank
- **Global Data Orgs**: WHO, EMA, FAIR principles alignment

## Operational layers (cross-references)

The strategy above is implemented through these documents in this directory:

- [`public-data-strategy.md`](public-data-strategy.md) — public dataset roadmap, privacy-preserving release, partnerships.
- [`dataset-catalog.md`](dataset-catalog.md) — stratification of multimodal datasets by access tier and infrastructure requirements.
- [`TECHNICAL_DATA_INFRASTRUCTURE.md`](TECHNICAL_DATA_INFRASTRUCTURE.md) — GCP project boundaries, GCS bucket taxonomy, VPC-SC, Healthcare API.
- [`paper-library-architecture.md`](paper-library-architecture.md) — sovereign library (Drive + Zotero metadata-only + Hypothes.is + future Neo4j).
- [`scholarly-knowledge-graph.md`](scholarly-knowledge-graph.md) — LinkML schema spanning bibliographic, scholarly, biomedical, and artifact entities.
- [`sssom-cross-ontology-mapping.md`](sssom-cross-ontology-mapping.md) — UMLS / MONDO / HP / CL / CHEBI / NCBITaxon / SNOMED CT mapping stack.
- [`monday-resource-boards.md`](monday-resource-boards.md) — Resources workspace as the human-resolution KG until Neo4j is fully online.
- [`linkml-kg-playbook.md`](linkml-kg-playbook.md) — pointer to the 22-chapter hands-on playbook.
- [`compliance/hipaa-compliance-framework.md`](compliance/hipaa-compliance-framework.md) and the [PHI checklist](compliance/phi-security-controls-checklist.md) — HIPAA program.
- [`policies/data-governance-policy.md`](policies/data-governance-policy.md), [`policies/controlled-data-access.md`](policies/controlled-data-access.md), [`policies/nih-nda-access-procedures.md`](policies/nih-nda-access-procedures.md) — governance and acquisition SOPs.
- [`schemas/multimodal-health-data-schema.md`](schemas/multimodal-health-data-schema.md) — JSON schemas for the multimodal patient record.
- [`templates/data-use-agreement-template.md`](templates/data-use-agreement-template.md) — outbound DUA template.

---

**Document Version**: 2.1
**Last Updated**: May 2026
**Next Review**: November 2026
**Owner**: Chief Data Officer, Cytognosis Foundation
